Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
NCT ID: NCT03662815
Last Updated: 2021-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2018-02-07
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iNeo-Vac-P01
Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;
Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01.
iNeo-Vac-P01
Neoantigen peptides
GM-CSF
immune adjuvant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iNeo-Vac-P01
Neoantigen peptides
GM-CSF
immune adjuvant
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 to 75 years old;
* The expected survival period is more than 6 months;
* ECOG score is 0 or 1;
* Patients with advanced tumors who fail to receive standard therapy, and those who are not suitable or refuse standard adjuvant therapy;
* Advanced malignant cancer diagnosed by pathology and imageology;
* At least one measurable lesions;
* To be able to obtain sufficient tumor tissue samples and blood samples for analysis, or to have genomic/exon/transcriptional data of tumor tissues and normal tissues, and the data meet the analysis requirements;
* The main organs function is normal, such as the heart, liver and kidney;
* Haematological index:
neutrophil count≥1.5×109/L
hemoglobin≥10g/dL
platelet count≥100×109/L
* Biochemical index:
Total bilirubin is less than or equal to 1.5 times the upper limit of normal value (ULN)
AST and ALT is less than or equal to 2.5 times the upper limit of normal value
Serum creatinine and urea nitrogen (BUN) is less than or equal to 1.5 times the upper limit of normal value
* Pregnant, lactating women and women of child-bearing age must have a negative pregnancy test within 7 days before entering the group, and short-term have no fertility plan, and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial;
* Good compliance, able to follow research protocols and follow-up procedures.
Exclusion Criteria
* No neoantigen was found in the sequencing data;
* There have been bone marrow or stem cell transplants;
* Systemic cancer treatment or other drugs under study were treated within 4 weeks prior to individualized tumor targeted polypeptides treatment;
* Received other polypeptide inoculation 4 weeks before treatment; Patients may not be vaccinated with other polypeptides 8 weeks after the last individualized tumor targeted polypeptides trentment;
* Active bacterial or fungal infections identified clinically (\>= level 2 of NCI-CTC edition 3);
* Patients with HIV, HCV, HBV infection, severe asthma, autoimmune disease, immunodeficiency or treated with immunosuppressive drugs;
* People infected with herpes virus (scabbed for more than 4 weeks is excluded);
* People infected with respiratory virus (cured for more than 4 weeks is excluded);
* Severe coronary or cerebrovascular disease, or other diseases that the investigators considered should to be exclusion;
* Drug abuse, Clinical, psychological or social factor result in affecting informed consent or research implementation;
* Have a history of drug or polypeptide allergies, or people who are allergic to other potential immunotherapies.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hangzhou Neoantigen Therapeutics Co., Ltd.
INDUSTRY
Sir Run Run Shaw Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yong Fang
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen JA, Gaudernack G, Buanes T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011 Mar 1;128(5):1120-8. doi: 10.1002/ijc.25449.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5.
Shou J, Mo F, Zhang S, Lu L, Han N, Liu L, Qiu M, Li H, Han W, Ma D, Guo X, Guo Q, Huang Q, Zhang X, Ye S, Pan H, Chen S, Fang Y. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy. Front Immunol. 2022 Sep 29;13:1000681. doi: 10.3389/fimmu.2022.1000681. eCollection 2022.
Fang Y, Mo F, Shou J, Wang H, Luo K, Zhang S, Han N, Li H, Ye S, Zhou Z, Chen R, Chen L, Liu L, Wang H, Pan H, Chen S. A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors. Clin Cancer Res. 2020 Sep 1;26(17):4511-4520. doi: 10.1158/1078-0432.CCR-19-2881. Epub 2020 May 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INEO-P-002
Identifier Type: -
Identifier Source: org_study_id